Patents Examined by Ilia I Ouspenski
  • Patent number: 10138299
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: November 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10117920
    Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 6, 2018
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
  • Patent number: 10087251
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 2, 2018
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Patent number: 10081681
    Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: September 25, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan J. Korman, Nils Lonberg, David J. Fontana, Andres A. Gutierrez, Mark J. Selby, Katherine E. Lewis
  • Patent number: 10077305
    Abstract: The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: September 18, 2018
    Assignee: MedImmune Limited
    Inventors: Andrew G. Buchanan, Ross Stewart, Mathieu Chodorge
  • Patent number: 10072090
    Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: September 11, 2018
    Assignees: AMGEN INC., MEDAREX INC.
    Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
  • Patent number: 10072082
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10071147
    Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: September 11, 2018
    Assignee: Taipei Veterans General Hospital
    Inventors: Keng-Li Lan, Yi-Sheng Shih, Keng-Hsin Lan
  • Patent number: 10072081
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 11, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Patent number: 10059768
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: August 28, 2018
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 10059769
    Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: August 28, 2018
    Assignee: I-MAB
    Inventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Patent number: 10058609
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: August 28, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 10052360
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Patent number: 10046008
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 14, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • Patent number: 10046047
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 14, 2018
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • Patent number: 10040864
    Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 7, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Fiona A. Harding
  • Patent number: 10035857
    Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 31, 2018
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Randolph J. Noelle, Li Wang
  • Patent number: 10023635
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 17, 2018
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Patent number: 10023637
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 17, 2018
    Assignees: Board of Regents, The University of Texas System, Memorial Sloan-Kettering Cancer Center
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Patent number: 10017575
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: July 10, 2018
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang